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Background: Currently available drugs for the treatment of ulcerative colitis (UC) include salicylates, thiopurines,
corticosteroids and new anti-tumour necrosis factor (TNF)-α biologics. Among these medications, corticosteroids in
children and adolescents may adversely affect the patients’ growth and development. Further, UC patients have
elevated and activated myeloid lineage leucocytes including the CD14 + CD16+ monocytes, which release TNF-α as
a significant exacerbating factor. Accordingly, depletion of these cells by granulocyte/monocyte adsorption (GMA)
should alleviate inflammation and promote UC remission. The objective of this study was to evaluate the efficacy of
GMA in children and adolescents in whom conventional first-line medications had failed to induce remission.
Methods: In a single centre setting, between 2007 and 2012, a total of 24 consecutive children and adolescents,
age 11–19 years were given mesalazine or sulphasalazine as a first-line medication. Seventeen patients relapsed or
did not respond to the first-line medications, and received GMA with the Adacolumn, 2 sessions in the first week,
and then weekly, up to 11 sessions. Patients who achieved a decrease of ≥5 in the clinical activity index (CAI) were
to continue with GMA, while non-responders were to receive 0.5 to 1.0 mg/kg/day prednisolone (PSL) plus
additional GMA sessions similar to GMA responder cases. At entry and week 12, patients were clinically and
endoscopically evaluated, allowing each patient to serve as her/his own control.
Results: Seven patients achieved remission with the first-line medications and did not receive GMA. Five patients
did not respond to the first 5 GMA sessions and received PSL plus GMA, while 12 patients responded to the first 5
GMA sessions and received additional sessions. At entry, the average CAI was 12.7 ± 2.5, range 8–17, and the
average endoscopic index was 8.5 ± 1.5, range 7–11. The corresponding values at week 12 were 2.1 ± 0.2, range 1–4
(P < 0.001) and 2.4 ± 0.2, range 1–4 (P < 0.001). PSL was tapered to 0 mg within 3 months.
Conclusions: With the strategy we applied in this study, all 24 consecutive patients achieved remission. In growing
patients with active UC refractory to first-line medications, GMA was associated with clinical remission and mucosal
healing, while in non-responders to GMA monotherapy, addition of a low dose PSL enhanced the efficacy of GMA and
tapering of the PSL dose soon after remission was not associated with UC relapse. Therefore, the majority of young
corticosteroid naive UC patients in whom first-line salicylates have failed may respond to GMA and be spared from
additional drug therapy. Avoiding corticosteroids at an early stage of UC should ensure better long-term clinical course.
Keywords: Paediatric inflammatory bowel disease, Ulcerative colitis, Adolescent, Prednisolone, Monotherapy, Myeloid
lineage leucocyte, Adsorptive granulocyte and monocyte apheresis* Correspondence: tomotaka@c.do-up.com
Department of Gastroenterology, Akitsu Prefectural Hospital, 4388 Akitsu cho,
Hiroshima 739-2402, Japan
© 2013 Tanaka et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Tanaka et al. BMC Gastroenterology 2013, 13:130 Page 2 of 8
http://www.biomedcentral.com/1471-230X/13/130Background
Ulcerative colitis (UC) is a debilitating chronic inflamma-
tory bowel disease (IBD) that afflicts millions of individ-
uals throughout the world and produces symptoms, which
impair performance and quality of life [1]. Factors which
initiate and perpetuate UC are not well understood yet.
Accordingly, up to now medical therapy of UC has been
empirical rather than based on a sound understanding
of disease pathology. The empirical approach to therapy
might in large part account for intolerance, treatment fail-
ure and adverse effects of pharmacologicals [2-4]. Histor-
ically, salicylates like sulphasalazine or 5-aminosalicylic
acid have been used as the first-line medication for mild
to moderate UC [1-3], while corticosteroids like prednisol-
one (PSL) are reserved for patients who do not respond to
the first-line medication or develop acute severe UC
[1,2,5]. Further, in children and adolescents with IBD,
currently available medications like corticosteroids can
adversely affect the patients’ growth and development [6],
while for biologics, long term safety is unknown [7,8].
However, there is evolving evidence for peripheral mye-
loid lineage leucocytes like the CD14 + CD16+ monocytes
as major sources of tumour necrosis factor (TNF)-α in
patients with IBD [9,10]. Furthermore, UC patients may
harbour elevated peripheral neutrophils as additional
sources of TNF-α [11-13]. Indeed, neutrophil activation
and prolonged survival is a feature of persistent intestinal
inflammation and histological examination of the mucosal
tissue reveals a spectrum of pathologic manifestations
among which presence of an abundance of neutrophils
accounts not only for the morphologic lesions of UC, but
also for the prevailing patterns of mucosal inflammation
[2,13]. Based on this background, the Adacolumn has been
developed for selective depletion of granulocytes and
monocytes (GM) by adsorptive apheresis (GMA). The col-
umn is filled with specially designed cellulose acetate beads
of 2mm in diameter as the column leucocytapheresis
carriers [14]. The carriers adsorb from the blood in the
column most of the GM together with a significant fraction
of platelets; lymphocytes are spared. In fact lymphocytes
increase after GMA [14,15], including the CD4 +CD25
high + phenotype, which is known as a key regulator of
immune function [16]. Here, we report on the efficacy and
safety of GMA in paediatrics and adolescents with active
UC in spite of receiving first-line medications.
Methods
Objective
Our major objective was to see if therapeutic granulocyte
and monocyte adsorption (GMA) is effective as remission
induction therapy in children and adolescents with active
UC who were glucocorticosteroid naïve and had a short
duration of UC (≤12 months). This was in line with our
intention to avoid administering corticosteroids and othermedications with safety concerns like cyclosporine and
biologics to very young patients.
GMA procedures
GMA with the Adacolumn is an established and officially
approved extracorporeal treatment intervention for patients
with active IBD in Japan [17-22]. Further, the Adacolumn
conforms to the European standards (CE-marked) and
therefore, in the countries of the European Union, its clin-
ical application to treat IBD is based on the CE-mark
[14,18-22]. In the present study, the Adacolumns were
purchased from JIMRO (Takasaki, Japan) and used as
previously described [14-19]. Briefly, the Adacolumn is a
single use medical device filled with specially designed cel-
lulose acetate beads of 2mm in diameter, which serve as
the column adsorptive leucocytapheresis carriers for FcγR
and complement receptor bearing leucocytes. Therefore,
the carriers selectively adsorb from the blood in the col-
umn most of the granulocytes, monocytes/macrophages
and a significant fraction of platelets; lymphocytes are
spared and subsequently increase [14,15]. Blood access
was via a venipuncture in the antecubital vein in one arm
and from the column outflow, blood return to the patient
was via a venipuncture in the contralateral arm. The
duration of one GMA session was 60 minutes, at 30ml/
minute. An optimum dose of sodium heparin (2000 units/
session) was administered during GMA as an anticoagu-
lant. In the present study, each patient was to receive 2
sessions in the first week and then weekly, up to 11
sessions in an outpatient setting.
Treatment design and efficacy assessment
A total of 24 children and adolescents with a definitive
diagnosis of UC were included in this investigation. The
patients’ major demographic variables are presented in
Table 1. These were all consecutive steroid naive patients
received at our IBD unit between 2007 and 2012. Patients’
UC clinical activity index (CAI) was determined at base-
line, prior to each GMA session and then within one week
post last session according to Rachmilewitz [23]. CAI ≤4
meant clinical remission. Similarly, patients’ UC disease
activity index (DAI) was determined based on colonoscopy
done at entry, after 5 GMA sessions and then within one
week following the final session or week 12 according to
Sutherland, et al. [24]. Endoscopic remission meant DAI <3
and absence of blood in stool.
As seen in Table 1, the duration of UC was short in these
cases. Following the diagnosis of UC, all patients were given
a salicylate (sulphasalazine or mesalazine, 2000-4000mg/
day) as the first-line medication. The treatment design
including the introduction of GMA for these patients is
shown in Figure 1. Any patient who achieved remission
with the first-line salicylate over a period of at least 4 weeks
was to continue with that medication, while patients who
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were selected for GMA. Further, it was decided that
patients who achieved a decrease of ≥5 points in the CAI
following 5 GMA sessions should continue with GMA,
while non-responders were to be given 0.5 - 1.0 mg/kg
bodyweight/day PSL orally plus additional GMA, up to 11
sessions without interrupting the GMA therapy. This was
to allow us assessing the efficacy of GMA in growing
patients as monotherapy or as a combination intervention.
However, PSL was to be tapered at 5mg/week when a
patient showed an improvement in the CAI score by at
least 5 points.
Ethical considerations
All treatment interventions applied in this study including
GMA are officially approved, and are routine therapeutic
options for patients with active IBD in Japan. Accordingly,
prior to the initiation of the treatments, this work was ap-
proved by ethic committees at the Hiroshima Chugoku
Rosai and Akitsu hospitals. Additionally, informed consent
was obtained from all patients after explaining the studyTable 1 Baseline demographic varialbles of 24 children and a
prednisolone (PSL)
Sub-group Age Gender Weight (Kg) UC loc
Responded to salicylate alone (n = 7) 17 F 37.5 left s
16 F 47.2 total s
13 M 33.8 total c
18 M 48.0 rect
17 M 55.5 rect
17 F 48.8 left side
11 F 33.0 left side
Responded to GMA alone (n = 12) 14 M 41.7 total c
16 F 41.8 left side
17 F 42.5 left side
11 F 41.5 left side
17 M 55 left side
15 M 40.6 left side
16 M 45.2 total c
12 F 41.2 left side
15 F 34.2 left side
14 F 41.2 left side
19 F 48.0 left side
17 F 44.8 total c
Responded to GMA + PSL (n = 5) 12 M 34 total c
13 F 31.5 left side
17 F 50 total c
15 F 41 total c
17 F 42.6 total c
CAI, clinical activity index; DAI endoscopic disease activity index; GMA, granulocyte/aim and the nature of the procedures involved. In all
under age cases, consent from one of the patients’ parents
was obtained. Further, adherence was made to the
Principle of Good Clinical Practice and the Helsinki Dec-
laration at all times.
Statistics
Where appropriate, data are presented as the average
(mean ± SD) values together with ranges. The overall
CAI and DAI scores at baseline and post GMA are com-
pared by using the paired t-test. Comparison of data sets
in sub-groups was done by using the Steel-Dwass test.
All statistical analyses were done by using the software




Among the 24 children and adolescents included in this
report (Table 1), 8 were female. Average age was 15.3 ± 2.3
years, range 11–19 years, average weight was 42.5 ± 6.5 kg,dolecents who responded to salicyte, GMA or GMA +
ation UC duration (month) CAI DAI Baseline medication
ide 3 10 7 Mesalazine, 80 mg/kg/day
ide 3 11 8 Mesalazine, 64 mg/kg/day
olitis 6 10 7 Mesalazine, 89 mg/kg/day
al 4 8 6 Mesalazine, 63 mg/kg/day
al 6 9 7 Mesalazine, 72 mg/kg/day
colitis 3 10 8 Mesalazine, 82 mg/kg/day
colitis 1 10 7 Mesalazine, 90 mg/kg/day
olitis 10 17 10 Sulphasalazine, 72 mg/kg/day
colitis 6 13 9 Mesalazine, 72 mg/kg/day
colitis 12 14 8 Mesalazine, 71 mg/kg/day
colitis 10 13 7 Mesalazine, 72 mg/kg/day
colitis 14 14 7 Sulphasalazine, 57 mg/kg/day
colitis 6 14 10 Sulphasalazine, 74 mg/kg/day
olitis 6 13 9 Sulphasalazine, 66 mg/kg/day
colitis 4 14 9 Mesalazine, 73 mg/kg/day
colitis 6 13 10 Mesalazine, 55 mg/kg/day
colitis 10 13 8 Mesalazine, 73 mg/kg/day
colitis 6 11 8 Mesalazine, 83 mg/kg/day
olitis 1 10 7 Mesalazine, 89 mg/kg/day
olitis 12 16 11 Sulphasalazine, 59 mg/kg/day
colitis 6 14 10 Sulphasalazine, 63 mg/kg/day
olitis 6 16 11 Mesalazine, 60 mg/kg/day
olitis 6 16 10 Sulphasalazine,73 mg/kg/day
olitis 8 15 10 Mesalazine, 70 mg/kg/day
monocyte adsorption; M, male; F, female; UC ulcerative colotis.
Active UC continued or patient 






CAI increased or remained 
unchanged (n = 5 cases)
CAI↓≥ 5 points 
(n = 12 cases)
Achieved remission with GMA
(GMA monotherapy, n = 12cases)
Achieved remission with  
GMA prednisolon ( n = 5 cases)
Children and adolescents with active ulcerative colitis (UC, n = 24 cases)
Sulphasalazine or mesalazine for ≥ 4 weeks
Achieved stable remission
(n = 7 cases)
Figure 1 Study design and the treatment outcomes in 24 children and adolescents with active ulcerative colitis.
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time of diagnosis to the first GMA session was 6.46 ± 3.41
months, range 1 month (shortest) to 12 months. Regarding
the severity of UC, average CAI was 12.7 ± 2.5, range 8–17,
and average DAI was 8.5 ± 1.5, range 7–11. Therefore, UC
was moderately active in the majority of the 24 patients.
Efficacy based on CAI and DAI
Figure 1 shows that 7 of 24 patients achieved clinical
remission (CAI ≤4) while on sulphasalazine or mesalazine.
These 7 patients were not included for GMA therapy. The
CAI measurements at entry and post GMA therapy for
the 17 patients who received GMA are presented in
Figure 2, while the corresponding DAI measurements are
presented in Figure 3. The average CAI scores prior to
GMA and post final session were 12.7 ± 2.5, range 8–17
and 2.1 ± 0.2, range 1–4 (P < 0.001), respectively. Only in
one case, CAI was 4 at post GMA therapy, but smaller
than 4 in 16 patients. Likewise, DAI values prior to the
first GMA session and at the end of GMA course were
8.5 ± 1.5, range 7–11, and 2.4 ± 0.2, range 1–4 (P < 0.001),
respectively. DAI was <3 in 9 cases (endoscopic remis-
sion), equal to 3 in 6 cases and 4 in 2 cases. Therefore, all
17 GMA-treated patients achieved clinical remission in-
cluding 9 with complete remission (mucosal healing).
As shown in Figure 1, 5 patients did not respond to the
first 5 GMA sessions and were given GMA plus PSL, but
the PSL dose was tapered to 0mg within 3 months. There-
fore, among 17 patients in the GMA group, 12 achieved
remission with GMA as monotherapy and 5 patients
achieved remission with GMA in combination with PSL.
Previously, we reported that patients with deep ulcers
together with extensive loss of the mucosal tissue at the
lesion sites were not likely to benefit from GMA [25]. Withthis in mind, colonoscopy was done at baseline in all pa-
tients who were to receive GMA therapy. As reported
above, these 24 patients had a short duration of UC and
none showed badly damaged mucosa, and this is reflected
in high clinical efficacy and endoscopic mucosal healing
rates in these patients. One typical colonoscopy image is
presented in Figure 4. This case, in spite of showing strong
inflammation in the mucosa and contact bleeding,
responded well to GMA.Sub-group analyses
As stated above, 7 patients achieved remission with sali-
cylate as the sole first-line medication (n7), 12 achieved
remission with GMA as monotherapy (n12), and 5 pa-
tients achieved remission with GMA + PSL (n5). We
were interested to see if baseline demographic variables
in these subgroups could predict the observed clinical
response. Prior to initiation of GMA, CAI measurements
in these sub-groups were 9.7 ± 0.9 (n7), 13.3 ± 1.2 (n12),
and 15.4 ± 0.9 (n5). The statistical significance levels were
as follows: n7 vs n12 (P < 0.01); n7 vs n5 (P < 0.01); n12
vs n5 (P = 0.04). Similarly, the average DAI scores in n7,
n12 and n5 subgroups were 7.1 ± 0.7, 8.5 ± 1.2 and 10.4 ±
0.6, respectively. The significance levels were: n7 vs n12
(P = 0.05, not significant); n7 vs n5 (P = 0.01); n12 vs n5
(P = 0.02). Based on the statistical analyses we carried
out, patients who responded to the first-line mesalazine
or sulphasalazine alone had a significantly lower average
CAI as compared with patients who received GMA.
Likewise, patients who achieved clinical remission with
GMA as monotherapy had significantly lower average
CAI core as compared with patients who achieved remis-
sion after receiving GMA + PSL.
Pre GMA Post GMA therapy
(Week 12)




























Figure 2 Clinical activity indices in 17 children and adolescents at entry, after 5 adsorptive granulocyte and monocyte apheresis (GMA)
sessions and then one week post final session (or week 12). Solid lines represent patients who achieved remission with GMA, while dotted
lines indicate patients received 0.5 to 1.0 mg/kg bodyweight/day prednisolone (PSL) in combination with GMA. All 17 patients achieved clinical
remission (CAI ≤4).
Tanaka et al. BMC Gastroenterology 2013, 13:130 Page 5 of 8
http://www.biomedcentral.com/1471-230X/13/130Maintenance rate of remission
The average follow-up time after the last GMA session
was 29.9 months, range 5 to 80 months. At the time of
this writing (January 2013), 15 of 24 patients were still in
remission (62.5%) with the salicylates as the only ongoing
medications. These were 7 of 7 cases in n7 (average 15
months), 6 of 12 cases in n12 (average 8.8 months) and 2

























Figure 3 Endoscopic disease activity indices (DAI) in 17 children and
monocyte apheresis (GMA) sessions and then one week post final ses
GMA without any additional medication, while dotted lines indicate patien
addition to GMA. All 17 patients had improvement of DAI including 9 withoutcome in connection with baseline CAI and the clinical
response to first-line medications, GMA monotherapy
and GMA+ PSL.
Treatment safety, feasibility and patients’ compliance
In general, GMA with the Adacolumn in our hospital is
very much favoured by our patients for its safety feature.






adolescents at entry, after 5 adsorptive granulocyte and
sion (or week 12). Solid lines represent patients who responded to
ts received 0.5 to 1.0 mg/kg bodyweight/day prednisolone (PSL) in
complete remission.
At entry Four months post GMA therapy
Figure 4 Typical endoscopic finding at entry and post GMA course in a patient who achieved complete remission by GMA as
monotherapy. This case, in spite of showing strong inflammation in the mucosa and contact bleeding, responded well to GMA with fully
restored mucosal vascular patterns.
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reality of clinical practice would suggest, venous access in
children is not as straightforward as in an adult patient.
Accordingly, blood access was a serious challenge and
needle pain was experienced by 8 of 17 patients (47.1%).
Other transient side effects were mild headache in 8 pa-
tients, nausea and light headedness in 6 patients (35.3%),
vomiting in 4 patients (23.5%). However, these adverse
events were not serious and all 17 cases completed their 11
GMA sessions according to the treatment schedule, com-
pliance was 100%. Further, although GMA carriers adsorb
a large fraction of ganulocytes and monocytes from the
blood which passes through the Adacolumn, but the levels
of these cells in the peripheral circulation were found not
to fall significantly [14] due to an influx of naive leucocytes
(CD10 negative neutrophils) from the marginal pools in-
cluding the bone marrow into the circulation [14]. The
naive leucocytes are thought to be less inflammatory [26].
Therefore, neither in this study nor in previous GMA stud-
ies [10,14-22], patients showed opportunistic infection.
Discussion
Regarding GMA as a therapeutic intervention in patients
with UC, it is of paramount importance to know that clin-
ical efficacy outcome reports vary from an 85% [25,27,28]
to a statistically insignificant level [29]. Regardless of the
outcome in a controlled study [29], our own experience
while treating over 200 patients during the past 12 years
indicates that first episode cases as well as steroid naïve
patients, notably those with a short duration of UC re-
spond well to GMA and are spared from drug therapy
[25,27,28,30]. It should be appropriate to mention here
that Yamamoto and colleagues [17] reported that patients
who responded to GMA had a better long-term clinical
outcome by avoiding corticosteroids during their first ac-
tive UC phase. In contrast, patients with deep mucosal le-
sions and extensive loss of the mucosal tissue at the lesion
sites together with those who have a long duration ofactive UC and exposure to multiple conventional drugs
including corticosteroids are not likely to benefit from
GMA [25,29-31]. The demography of the young patients
in this report was consistent with the GMA responder fea-
tures. Accordingly, we thought that these patients should
respond well to GMA and be spared from additional
pharmacologic intervention. The therapeutic outcomes in
these 24 cases might be summarised as follows.
Following the diagnosis of UC, every one of these chil-
dren/adolescents was given a salicylate as the first-line
medication. Among the 24 patients, 17 developed active
disease while on a salicylate or did not respond to the
first-line medications. Most of the 17 patients did respond
to GMA and avoided additional pharmacologic therapy.
Only in a minority of the 24 patients corticosteroid was
used, which was discontinued when a patient showed
improvement. Therefore, 3 months after the initiation of
GMA therapy, all 24 young patients were in clinical remis-
sion, and none was on a corticosteroid. As reported above,
the efficacy of GMA is intimately related to patients’
endoscopic findings at entry [25,29,30]. With this in mind,
colonoscopy was done at baseline in all patients who were
to receive GMA. However, as mentioned above, these 24
patients had a short duration of UC and none showed
badly damaged mucosa, and this is reflected in a high clin-
ical efficacy and endoscopic mucosal healing rates in these
patients. Generally, GMA has a good safety profile, and
therefore, apart from needle pain in a significant fraction
of these youngsters, we had no serious safety concern to
report here. In spite of the needle pain, all 17 patients
completed their GMA course according to the protocol.
A recent expert report [32] recommends that first epi-
sode cases or patients with a single inflammatory exacerba-
tion in a 12-month period should receive 5-aminosalicylate
instead of corticosteroids due to safety concerns. Adverse
effects of drug based medications in very young patients
can be a serious addition to the morbidity associated with
IBD. Fortunately, it appears that drug naïve patients
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the best time to apply GMA is immediately after a clinical
relapse, which means a short duration of active disease
[31]. As GMA is a non-drug intervention, it is unlikely to
cause refractoriness.
At this point, we like to make specific comments on the
merit and limitations of this report. Here we describe the
outcomes in 24 young patients who were treated in a con-
secutive setting over a period of 5 years. Apart from being
an open study, 5 patients who did not improve after the
first 5 GMA sessions received PSL, while GMA was con-
tinued. Therefore, we can not claim that these 5 cases
might not have achieved remission with PSL alone. How-
ever, as stated above, our objective was to avoid corticoste-
roids in these young patients. The 19 patients who did not
receive corticosteroids should have a better long-term
clinical course as reported for adult patients [17]. With
this in mind, PSL was tapered to 0mg when a patient im-
proved, and this did not provoke a relapse. Likewise, our
subgroup analyses showed that patients with a lower entry
CAI responded well to the first-line medications or GMA
monotherapy, while those with a significantly higher CAI
score needed PSL. In the same order, patients had better
maintenance rate of remission (see Results section). We
are aware that these subgroups had a small number of
cases and further studies in larger cohorts of patients are
expected. Additionally, we have referred to patients who
responded to GMA without adding any other medication
as GMA monotherapy. One could logically argue that
those patients were on concomitant salicylates. However,
except in one case, salicylates had been continued for at
least 4 weeks prior to GMA in 11 of the 12 GMA mono-
therapy cases and all 17 GMA-treated patients had re-
lapsed or had active disease while on a salicylate. We
believe that the superiority of GMA over corticosteroids
warrants to be shown in a future randomised controlled
trial in large cohorts of paediatric UC patients in whom
first-line medications have failed; patients in one arm
should receive GMA, while patients in another arm
receive corticosteroid as remission induction therapy.
Conclusions
In this study, children and adolescents with UC who were
corticosteroid naïve and had a relatively short duration
of UC were given first-line medications and those who
did not achieve remission were given GMA as a non-
pharmacologic treatment intervention. Of 24 patients only
5 patients received corticosteroid, but only over a short
period of time. GMA was associated with clinical remis-
sion and mucosal healing. Therefore, the majority of
young UC patients in whom first-line salicylates have
failed may respond well to GMA and be spared from cor-
ticosteroids and other pharmacologics with safety concern.
Further, in our hospital, GMA is very much favoured bypatients for its safety profile and being a non-drug inter-
vention. This is of significant clinical interest in children
in whom long-term drug based intervention can adversely
affect the patient’s growth and development. A future
randomised controlled trial in large cohorts of paediatric
UC patients should strengthen the findings of this study.
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